

Sheet 1 of 1

PRIORITY TO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01382K

SERIAL NO.:

10/057,629

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:

Harry R. Davis

FILING DATE:

January 25, 2002

GROUP:

1614

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MS	AA	<b>Exhibit A:</b> SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary
	AB	<b>Exhibit B:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AC	<b>Exhibit C:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AD	<b>Exhibit D:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AE	<b>Exhibit E:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AF	<b>Exhibit F:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AG	<b>Exhibit G:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AH	<b>Exhibit H:</b> SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AI	<b>Exhibit 1:</b> Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585
	AJ	<b>Exhibit 2:</b> Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112
	AK	<b>Exhibit 3:</b> Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566
	AL	<b>Exhibit 4:</b> Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130
NS	AM	<b>Exhibit 5:</b> Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8
EXAMINER		DATE CONSIDERED 10/16/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.